Finally, in both in vitro and in vivo models for inflammatory bowel disease (IBD), both valproic acid and SAHA drastically reduced TNF-α and IFN-γ levels, suggesting that HDAC inhibitors may prove fruitful as a novel therapy for the treatment of IBD (as reviewed in [122]). This evidence concerns the gene HDAC9 and inflammatory bowel disease.